| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $112.5M | +52.1% |
| SG&A Expense | $33.0M | +45.9% |
| Operating Income | -$247.4M | -98.1% |
| Net Income | -$242.8M | -97.8% |
| EPS (Basic) | -$1.99 | -7.6% |
| EPS (Diluted) | -$1.99 | -7.6% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $284.2M | -21.2% |
| Short-term Investments | $151.4M | +180.4% |
| Current Assets | $444.5M | +5.8% |
| Total Assets | $514.9M | +2.7% |
| Current Liabilities | $48.7M | +84.6% |
| Total Liabilities | $103.1M | +129.6% |
| Stockholders' Equity | $411.9M | -9.8% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$103.3M | -29.7% |
| Capital Expenditures | $14.6M | +29.9% |
| Investing Cash Flow | -$71.1M | -10.0% |
| Financing Cash Flow | $98.1M | -77.7% |
| Free Cash Flow | -$117.8M | -29.7% |